HIF

Isoform-selective Products

Signaling Pathway

HIF Signaling Pathway

HIF Products

  • All (35)
  • HIF Inhibitors (23)
  • HIF Activator (1)
  • HIF Antagonists (2)
  • HIF Modulators (9)
  • New HIF Products
Catalog No. Product Name Information Product Use Citations Product Validations
S1007 Roxadustat (FG-4592) Roxadustat (FG-4592) is an HIF-α prolyl hydroxylase inhibitor in a cell-free assay, stabilizes HIF-2 and induces EPO production. Roxadustat potentiates RSL3 induced ferroptosis. Phase 3.
Cell Rep, 2024, 43(1):113606.
Signal Transduct Target Ther, 2023, 10.1038/s41392-023-01578-2
Signal Transduct Target Ther, 2023, 8(1):355
S1233 2-Methoxyestradiol (2-MeOE2) 2-Methoxyestradiol (2-MeOE2, NSC 659853, 2-ME2) depolymerizes microtubules and blocks HIF-1α nuclear accumulation and HIF-transcriptional activity. 2-Methoxyestradiol induces both autophagy and apoptosis in various carcinogenic cell lines.
Cell Death Dis, 2023, 14(4):234
JCI Insight, 2023, 8(23)e164968
Phytomedicine, 2023, 115:154809
S7612 PX-478 2HCl PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. PX-478 2HCl induces apoptosis and has anti-tumor activity. Phase 1.
Nat Cancer, 2023, 4(10):1508-1525
J Exp Clin Cancer Res, 2023, 42(1):340
EMBO Mol Med, 2023, e17209.
S5742 Deferoxamine mesylate Deferoxamine mesylate is the mesylate salt of Deferoxamine, which forms iron complexes and is used as a chelating agent. Deferoxamine is a ferroptosis inhibitor that stabilizes HIF-1α expression and improves HIF-1α transactivity in hypoxic and hyperglycemic states in vitro. Deferoxamine decreases beta-amyloid (Aβ) deposition and induces autophagy.Please do not prepare stock solutions with normal saline or PBS, as precipitation may occur.
Redox Biol, 2024, 69:103008
Ecotoxicol Environ Saf, 2024, 270:115889
J Cancer, 2024, 15(3):685-698
S7309 BAY 87-2243 BAY 87-2243 is a potent and selective hypoxia-inducible factor-1 (HIF-1) inhibitor. BAY 87-2243 inhibits mitochondrial complex I activity, thus triggering a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis. BAY 87-2243 exerts antitumor activity. Phase 1.
Mol Ther Nucleic Acids, 2023, 31:421-436
Mol Med, 2023, 29(1):91
Biomater Res, 2023, 27(1):11
S7483 DMOG DMOG (Dimethyloxalylglycine) is an antagonist of α-ketoglutarate cofactor and inhibitor for HIF prolylhydroxylase, leading to stabilisation and accumulation of HIF-1α protein in the nucleus. DMOG enhances autophagy.
Nucleic Acids Res, 2023, gkad796
Redox Biol, 2023, 66:102858
EMBO J, 2023, 42(20):e113743
S7946 KC7F2 KC7F2 is a selective HIF-1α translation inhibitor with IC50 of 20 μM in a cell-based assay.
J Exp Clin Cancer Res, 2023, 42(1):25
Cell Mol Gastroenterol Hepatol, 2023, 10.1016/j.jcmgh.2023.07.012
Cell Mol Gastroenterol Hepatol, 2023, 16(5):823-846
S7958 Lificiguat (YC-1) Lificiguat (YC-1) is an nitric oxide (NO)-independent activator of soluble guanylyl cyclase(sGC) and an inhibitor of Hypoxia-inducible factor-1alpha (HIF-1alpha).
Hepatol Commun, 2024, 8(1)e0350
Bioact Mater, 2023, 19:690-702
J Neuroinflammation, 2023, 20(1):82
S2919 IOX2 IOX2 (JICL38) is a potent inhibitor of HIF-1α prolyl hydroxylase-2 (PHD2) with IC50 of 21 nM in a cell-free assay, >100-fold selectivity over JMJD2A, JMJD2C, JMJD2E, JMJD3, or the 2OG oxygenase FIH.
Cell Rep Med, 2024, 5(2):101400
Oncogene, 2022, 41(13):1944-1958
Elife, 2022, 11e69348
S2410 Paeoniflorin (NSC 178886) Paeoniflorin (NSC 178886,Peoniflorin) is a herbal constituent extracted from the root of Paeonia albiflora Pall. Paeoniflorin reduces COX-2 expression. Paeoniflorin alleviates liver fibrosis by inhibiting HIF-1α through mTOR-dependent pathway.
Kaohsiung J Med Sci, 2023, 10.1002/kjm2.12736
J Pers Med, 2022, 12(2)258
Bioengineered, 2022, 13(5):13622-13631
S8441 CAY10585 (LW 6) CAY10585 (LW 6) is a hypoxia-inducible factor 1(HIF) inhibitor which potently inhibits HIF-1α accumulation by degrading HIF-1α without affecting the HIF-1a mRNA levels during hypoxia. LW6 inhibits HIF and MDH2 expression with IC50 values of 4.4 and 6.3 μM, respectively.
Sci Adv, 2023, 9(1):eabo7555
Front Immunol, 2022, 13:888719
Neural Regen Res, 2022, 17(3):577-586
S8138 Molidustat (BAY 85-3934) Molidustat (BAY 85-3934) is a potent hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor with IC50 of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD, respectively. Phase 2.
Bone Res, 2023, 11(1):7
Cancers (Basel), 2023, 15(6)1846
Cell Rep, 2021, 35(3):109020
S8352 PT2385 PT2385 is a HIF-2α antagonist with luciferase EC50 of 27 nM and no significant off-target activity.
Nat Commun, 2023, 14(1):2790
Biol Res, 2023, 56(1):17
J Cell Mol Med, 2023, 27(2):246-258
S5804 N-Acetylcysteine amide N-acetylcysteine amide is a membrane penetrating antioxidant with anti-inflamatory activity through regulation of activation of NF-κB and HIF-1α as well as modulation of ROS.
Nat Commun, 2023, 14(1):5165
Nat Commun, 2023, 14(1):5165
J Mol Biol, 2023, 435(13):168128
S8771 IDF-11774 IDF-11774 is a hypoxia-inducible factor-1 (HIF-1) inhibitor. It reduces the HRE-luciferase activity of HIF-1α (IC50 = 3.65 μM) and blocks HIF-1α accumulation under hypoxia in HCT116 human colon cancer cells.
Nat Commun, 2022, 13(1):7335
mSystems, 2022, 7(4):e0038022
Chem Biol Interact, 2022, 369:110262
S8443 MK-8617 MK-8617 is an orally active pan-inhibitor of Hypoxia-inducible factor prolyl hydroxylase 1−3 (HIF PHD1−3), inhibiting PHD1, 2, 3 with IC50s of 1.0, 1.0 and 14 nM, respectively.
PeerJ, 2023, 11:e15591
bioRxiv, 2021, 10.1101/2021.08.26.456853
FASEB J, 2020, 34(2):2344-2358
S8171 Daprodustat (GSK1278863) Daprodustat (GSK1278863) is an orally administered hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor. Phase 2.
Cell Rep, 2021, 35(3):109020
FASEB J, 2020, 34(2):2344-2358
Cancer Res, 2019, 79(10):2564-2579
S7979 FG-2216 FG-2216 is a potent, and orally active HIF prolyl 4-hydroxylase inhibitor with IC50 of 3.9 μM for PHD2. Phase 2.
J Photochem Photobiol B, 2020, 210:111980
FASEB J, 2020, 34(2):2344-2358
S6490 Vadadustat Vadadustat (AKB-6548, B-506, PG-1016548) is a novel, titratable, oral HIF-PH inhibitor.
Drug Test Anal, 2020, 10.1002/dta.2917
S6400 Glucosamine Glucosamine (2-amino-2-deoxy-D-glucose) is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids. It is commonly used as a treatment for osteoarthritis. Glucosamine(GS) treatment selectively downregulates HIF-1α at the protein level in YD-8 cells via interference of production of the citric acid cycle metabolites.
Cell Death Dis, 2020, 11(7):503
S9656 Enarodustat (JTZ-951) Enarodustat (JTZ-951) is a potent and orally active HIF prolyl hydroxylase inhibitor with IC50 of 0.22 μM for PHD2 and EC50 of 5.7 μM for EPO release from Hep3B cells. Enarodustat has the potential for the treatment of renal anemia.
Mol Med, 2023, 29(1):61
S2937 SYP-5 SYP-5 is an inhibitor of Hypoxia-inducible factor-1 (HIF-1) that suppresses tumor cell migration and invasion, as well as tumor angiogenesis.
Chem Biol Interact, 2022, 369:110262
S6684 IOX4 IOX4 is a potent and selective HIF prolyl-hydroxylase 2 (PHD2) inhibitor with IC50 of 1.6 nM. IOX4 induces HIFα in various mouse tissues and human cell lines.
J Immunol, 2023, 211(2):261-273
S0729 TP0463518 TP0463518 is a potent hypoxia-inducible factor prolyl hydroxylases (PHDs) inhibitor with Ki of 5.3 nM for human PHD2. TP0463518 inhibits human PHD1, human PHD3 and monkey PHD2 with IC50 of 18 nM, 63 nM and 22 nM, respectively.
S9699 Desidustat Desidustat (ZYAN1, ZYAN1-1001), an antianaemic drug candidate, is an orally active hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor (HIF-PHI) that stimulates erythropoiesis.
S8886 Belzutifan (PT2977) Belzutifan (PT2977), an orally active and selective HIF-2α inhibitor, increases potency and improves pharmacokinetic profile, providing a potential treatment for clear cell renal cell carcinoma (ccRCC).
S8351 PT2399 PT2399 is a potent and orally available antagonist of HIF-2 that selectively disrupts the heterodimerization of HIF-2α with HIF-1β.
S8449 VH298 VH298 is a potent VHL (Von Hippel-Lindau, the E3 ligase) inhibitor that stabilizes HIF-α. VH298 blocks the VHL:HIF-α interaction with Kd of 90 nM in isothermal titration calorimetry (ITC) and 80 nM in a competitive fluorescence polarization assay. VH-298 can be used in PROTAC technology.
Eur J Med Chem, 2024, 268:116202
S8617New Acriflavine Acriflavine is a HIF-1 dimerization inhibitor and have potent inhibitory effects on tumor growth and vascularization. It is used as fluorescent dye for labeling high molecular weight RNA.
E0807 NHWD-870 NHWD-870 inhibits CSF1 expression through suppressing BRD4 and its target HIF1α.
E2168 PHD-1-IN-1 PHD-1-IN-1 is an orally active and potent HIF prolylhydroxylase domain-1 (PHD-1) inhibitor with an IC50 of 0.034 μM
E1661New Adaptaquin Adaptaquin is an inhibitor of hypoxia-inducible factor prolyl hydroxylase 2 (HIF-PHD2), with an IC50 of 2 μM. Adaptaquin also inhibits lipid peroxidation and maintains mitochondrial function.
E1712New FM19G11 FM19G11 is a hypoxia-inducible factor-1-alpha (HIF-1α) inhibitor, and it inhibits hypoxia-induced luciferase activity with an IC50 of 80 nM in HeLa cells.
S3589 Bendazol Bendazol (2-Benzylbenzimidazole, Dibazol, Dibazole, Bendazole, Tromasedan) is a hypotensive drug that enhances NO synthase activity in renal glomeruli and collecting tubules. Bendazol inhibits the progression of form-deprivation myopia (FDM) and suppresses the upregulation of HIF-1α.
E1618New TC-S 7009 TC-S 7009 is a potent and selective inhibitor of HIF-2α with a Kd value of 81 nM. TC-S 7009 is more selective for HIF-2α than HIF-1α. It disrupts HIF-2α heterodimerization, decreases DNA-binding activity, and reduces HIF-2α target gene expression.
S1233 2-Methoxyestradiol (2-MeOE2) 2-Methoxyestradiol (2-MeOE2, NSC 659853, 2-ME2) depolymerizes microtubules and blocks HIF-1α nuclear accumulation and HIF-transcriptional activity. 2-Methoxyestradiol induces both autophagy and apoptosis in various carcinogenic cell lines.
Cell Death Dis, 2023, 14(4):234
JCI Insight, 2023, 8(23)e164968
Phytomedicine, 2023, 115:154809
S7612 PX-478 2HCl PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. PX-478 2HCl induces apoptosis and has anti-tumor activity. Phase 1.
Nat Cancer, 2023, 4(10):1508-1525
J Exp Clin Cancer Res, 2023, 42(1):340
EMBO Mol Med, 2023, e17209.
S7309 BAY 87-2243 BAY 87-2243 is a potent and selective hypoxia-inducible factor-1 (HIF-1) inhibitor. BAY 87-2243 inhibits mitochondrial complex I activity, thus triggering a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis. BAY 87-2243 exerts antitumor activity. Phase 1.
Mol Ther Nucleic Acids, 2023, 31:421-436
Mol Med, 2023, 29(1):91
Biomater Res, 2023, 27(1):11
S7946 KC7F2 KC7F2 is a selective HIF-1α translation inhibitor with IC50 of 20 μM in a cell-based assay.
J Exp Clin Cancer Res, 2023, 42(1):25
Cell Mol Gastroenterol Hepatol, 2023, 10.1016/j.jcmgh.2023.07.012
Cell Mol Gastroenterol Hepatol, 2023, 16(5):823-846
S7958 Lificiguat (YC-1) Lificiguat (YC-1) is an nitric oxide (NO)-independent activator of soluble guanylyl cyclase(sGC) and an inhibitor of Hypoxia-inducible factor-1alpha (HIF-1alpha).
Hepatol Commun, 2024, 8(1)e0350
Bioact Mater, 2023, 19:690-702
J Neuroinflammation, 2023, 20(1):82
S2410 Paeoniflorin (NSC 178886) Paeoniflorin (NSC 178886,Peoniflorin) is a herbal constituent extracted from the root of Paeonia albiflora Pall. Paeoniflorin reduces COX-2 expression. Paeoniflorin alleviates liver fibrosis by inhibiting HIF-1α through mTOR-dependent pathway.
Kaohsiung J Med Sci, 2023, 10.1002/kjm2.12736
J Pers Med, 2022, 12(2)258
Bioengineered, 2022, 13(5):13622-13631
S8441 CAY10585 (LW 6) CAY10585 (LW 6) is a hypoxia-inducible factor 1(HIF) inhibitor which potently inhibits HIF-1α accumulation by degrading HIF-1α without affecting the HIF-1a mRNA levels during hypoxia. LW6 inhibits HIF and MDH2 expression with IC50 values of 4.4 and 6.3 μM, respectively.
Sci Adv, 2023, 9(1):eabo7555
Front Immunol, 2022, 13:888719
Neural Regen Res, 2022, 17(3):577-586
S8771 IDF-11774 IDF-11774 is a hypoxia-inducible factor-1 (HIF-1) inhibitor. It reduces the HRE-luciferase activity of HIF-1α (IC50 = 3.65 μM) and blocks HIF-1α accumulation under hypoxia in HCT116 human colon cancer cells.
Nat Commun, 2022, 13(1):7335
mSystems, 2022, 7(4):e0038022
Chem Biol Interact, 2022, 369:110262
S6400 Glucosamine Glucosamine (2-amino-2-deoxy-D-glucose) is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids. It is commonly used as a treatment for osteoarthritis. Glucosamine(GS) treatment selectively downregulates HIF-1α at the protein level in YD-8 cells via interference of production of the citric acid cycle metabolites.
Cell Death Dis, 2020, 11(7):503
S9656 Enarodustat (JTZ-951) Enarodustat (JTZ-951) is a potent and orally active HIF prolyl hydroxylase inhibitor with IC50 of 0.22 μM for PHD2 and EC50 of 5.7 μM for EPO release from Hep3B cells. Enarodustat has the potential for the treatment of renal anemia.
Mol Med, 2023, 29(1):61
S2937 SYP-5 SYP-5 is an inhibitor of Hypoxia-inducible factor-1 (HIF-1) that suppresses tumor cell migration and invasion, as well as tumor angiogenesis.
Chem Biol Interact, 2022, 369:110262
S6684 IOX4 IOX4 is a potent and selective HIF prolyl-hydroxylase 2 (PHD2) inhibitor with IC50 of 1.6 nM. IOX4 induces HIFα in various mouse tissues and human cell lines.
J Immunol, 2023, 211(2):261-273
S0729 TP0463518 TP0463518 is a potent hypoxia-inducible factor prolyl hydroxylases (PHDs) inhibitor with Ki of 5.3 nM for human PHD2. TP0463518 inhibits human PHD1, human PHD3 and monkey PHD2 with IC50 of 18 nM, 63 nM and 22 nM, respectively.
S9699 Desidustat Desidustat (ZYAN1, ZYAN1-1001), an antianaemic drug candidate, is an orally active hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor (HIF-PHI) that stimulates erythropoiesis.
S8886 Belzutifan (PT2977) Belzutifan (PT2977), an orally active and selective HIF-2α inhibitor, increases potency and improves pharmacokinetic profile, providing a potential treatment for clear cell renal cell carcinoma (ccRCC).
S8449 VH298 VH298 is a potent VHL (Von Hippel-Lindau, the E3 ligase) inhibitor that stabilizes HIF-α. VH298 blocks the VHL:HIF-α interaction with Kd of 90 nM in isothermal titration calorimetry (ITC) and 80 nM in a competitive fluorescence polarization assay. VH-298 can be used in PROTAC technology.
Eur J Med Chem, 2024, 268:116202
S8617New Acriflavine Acriflavine is a HIF-1 dimerization inhibitor and have potent inhibitory effects on tumor growth and vascularization. It is used as fluorescent dye for labeling high molecular weight RNA.
E0807 NHWD-870 NHWD-870 inhibits CSF1 expression through suppressing BRD4 and its target HIF1α.
E2168 PHD-1-IN-1 PHD-1-IN-1 is an orally active and potent HIF prolylhydroxylase domain-1 (PHD-1) inhibitor with an IC50 of 0.034 μM
E1661New Adaptaquin Adaptaquin is an inhibitor of hypoxia-inducible factor prolyl hydroxylase 2 (HIF-PHD2), with an IC50 of 2 μM. Adaptaquin also inhibits lipid peroxidation and maintains mitochondrial function.
E1712New FM19G11 FM19G11 is a hypoxia-inducible factor-1-alpha (HIF-1α) inhibitor, and it inhibits hypoxia-induced luciferase activity with an IC50 of 80 nM in HeLa cells.
S3589 Bendazol Bendazol (2-Benzylbenzimidazole, Dibazol, Dibazole, Bendazole, Tromasedan) is a hypotensive drug that enhances NO synthase activity in renal glomeruli and collecting tubules. Bendazol inhibits the progression of form-deprivation myopia (FDM) and suppresses the upregulation of HIF-1α.
E1618New TC-S 7009 TC-S 7009 is a potent and selective inhibitor of HIF-2α with a Kd value of 81 nM. TC-S 7009 is more selective for HIF-2α than HIF-1α. It disrupts HIF-2α heterodimerization, decreases DNA-binding activity, and reduces HIF-2α target gene expression.
S5742 Deferoxamine mesylate Deferoxamine mesylate is the mesylate salt of Deferoxamine, which forms iron complexes and is used as a chelating agent. Deferoxamine is a ferroptosis inhibitor that stabilizes HIF-1α expression and improves HIF-1α transactivity in hypoxic and hyperglycemic states in vitro. Deferoxamine decreases beta-amyloid (Aβ) deposition and induces autophagy.Please do not prepare stock solutions with normal saline or PBS, as precipitation may occur.
Redox Biol, 2024, 69:103008
Ecotoxicol Environ Saf, 2024, 270:115889
J Cancer, 2024, 15(3):685-698
S8352 PT2385 PT2385 is a HIF-2α antagonist with luciferase EC50 of 27 nM and no significant off-target activity.
Nat Commun, 2023, 14(1):2790
Biol Res, 2023, 56(1):17
J Cell Mol Med, 2023, 27(2):246-258
S8351 PT2399 PT2399 is a potent and orally available antagonist of HIF-2 that selectively disrupts the heterodimerization of HIF-2α with HIF-1β.
S1007 Roxadustat (FG-4592) Roxadustat (FG-4592) is an HIF-α prolyl hydroxylase inhibitor in a cell-free assay, stabilizes HIF-2 and induces EPO production. Roxadustat potentiates RSL3 induced ferroptosis. Phase 3.
Cell Rep, 2024, 43(1):113606.
Signal Transduct Target Ther, 2023, 10.1038/s41392-023-01578-2
Signal Transduct Target Ther, 2023, 8(1):355
S7483 DMOG DMOG (Dimethyloxalylglycine) is an antagonist of α-ketoglutarate cofactor and inhibitor for HIF prolylhydroxylase, leading to stabilisation and accumulation of HIF-1α protein in the nucleus. DMOG enhances autophagy.
Nucleic Acids Res, 2023, gkad796
Redox Biol, 2023, 66:102858
EMBO J, 2023, 42(20):e113743
S2919 IOX2 IOX2 (JICL38) is a potent inhibitor of HIF-1α prolyl hydroxylase-2 (PHD2) with IC50 of 21 nM in a cell-free assay, >100-fold selectivity over JMJD2A, JMJD2C, JMJD2E, JMJD3, or the 2OG oxygenase FIH.
Cell Rep Med, 2024, 5(2):101400
Oncogene, 2022, 41(13):1944-1958
Elife, 2022, 11e69348
S8138 Molidustat (BAY 85-3934) Molidustat (BAY 85-3934) is a potent hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor with IC50 of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD, respectively. Phase 2.
Bone Res, 2023, 11(1):7
Cancers (Basel), 2023, 15(6)1846
Cell Rep, 2021, 35(3):109020
S5804 N-Acetylcysteine amide N-acetylcysteine amide is a membrane penetrating antioxidant with anti-inflamatory activity through regulation of activation of NF-κB and HIF-1α as well as modulation of ROS.
Nat Commun, 2023, 14(1):5165
Nat Commun, 2023, 14(1):5165
J Mol Biol, 2023, 435(13):168128
S8443 MK-8617 MK-8617 is an orally active pan-inhibitor of Hypoxia-inducible factor prolyl hydroxylase 1−3 (HIF PHD1−3), inhibiting PHD1, 2, 3 with IC50s of 1.0, 1.0 and 14 nM, respectively.
PeerJ, 2023, 11:e15591
bioRxiv, 2021, 10.1101/2021.08.26.456853
FASEB J, 2020, 34(2):2344-2358
S8171 Daprodustat (GSK1278863) Daprodustat (GSK1278863) is an orally administered hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor. Phase 2.
Cell Rep, 2021, 35(3):109020
FASEB J, 2020, 34(2):2344-2358
Cancer Res, 2019, 79(10):2564-2579
S7979 FG-2216 FG-2216 is a potent, and orally active HIF prolyl 4-hydroxylase inhibitor with IC50 of 3.9 μM for PHD2. Phase 2.
J Photochem Photobiol B, 2020, 210:111980
FASEB J, 2020, 34(2):2344-2358
S6490 Vadadustat Vadadustat (AKB-6548, B-506, PG-1016548) is a novel, titratable, oral HIF-PH inhibitor.
Drug Test Anal, 2020, 10.1002/dta.2917
S8617New Acriflavine Acriflavine is a HIF-1 dimerization inhibitor and have potent inhibitory effects on tumor growth and vascularization. It is used as fluorescent dye for labeling high molecular weight RNA.
E1661New Adaptaquin Adaptaquin is an inhibitor of hypoxia-inducible factor prolyl hydroxylase 2 (HIF-PHD2), with an IC50 of 2 μM. Adaptaquin also inhibits lipid peroxidation and maintains mitochondrial function.
E1712New FM19G11 FM19G11 is a hypoxia-inducible factor-1-alpha (HIF-1α) inhibitor, and it inhibits hypoxia-induced luciferase activity with an IC50 of 80 nM in HeLa cells.
E1618New TC-S 7009 TC-S 7009 is a potent and selective inhibitor of HIF-2α with a Kd value of 81 nM. TC-S 7009 is more selective for HIF-2α than HIF-1α. It disrupts HIF-2α heterodimerization, decreases DNA-binding activity, and reduces HIF-2α target gene expression.

Choose Selective HIF Inhibitors

Tags: HIF pathway | HIF cancer | hypoxia-inducible factor cancer | HIF-1 cancer | HIF activation | HIF-1 pathway | hypoxia-inducible factor pathway | HIF-1 activation | HIF-1α pathway | HIF inhibitor review